**Prescription of antiepileptic medicines including valproate in pregnant women:**

 **a study in three European countries**

SHORT RUNNING TITLE – Antiepileptic medicines in European pregnant women

Caroline Hurault-Delarue1\*, Joan K Morris2\*, Rachel Charlton3, Rosa Gini4, Maria Loane5, Anna Pierini6, Aurora Puccini7, Amanda Neville8, Julia Snowball3, Christine Damase-Michel1, on behalf of the EUROmediSAFE consortium

**Author Affiliations:**

\* Joint first authors

1: Pharmacologie Faculté de Médecine, Université Paul-Sabatier Toulouse III, CHU Toulouse, UMR INSERM 1027, France;

2: Population Health Research Institute, St George’s University of London, UK;

3: Department of Pharmacy & Pharmacology, University of Bath, Bath, UK;

4: Agenzia regionale di sanità della Toscana, Italy;

5: Faculty Life & Health Sciences, Ulster University, Newtownabbey, Northern Ireland;

6: Institute of Clinical Physiology - National Research Council (IFC-CNR)/Fondazione Toscana “Gabriele Monasterio”, Pisa, Italy;

7: Drug Policy Service, Emilia Romagna Region Health Authority, Bologna, Italy;

8: IMER (Emilia Romagna Registry of Birth Defects), Centre for Clinical and Epidemiological Research, University of Ferrara and Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy;

Corresponding author:

Joan Morris

Population Health Research Institute, St George’s, University of London, Cranmer Terrace, SW17 ORE

email: jmorris@sgul.ac.uk phone number: +44 (0)208 725 1324

Orcid: 0000-0002-7164-612X

Key Words: Antiepileptic drugs, Pregnancy, Europe, Valproate, Linkage

# Key points

* Exposure to some AEDs during pregnancy increases the risk of major congenital malformations in the offspring, such as neural tube defects and cleft palate. The risk varies by AED with valproate having the highest risk.
* Antiepileptic drugs (AED) should be prescribed with caution during pregnancy.
* The study using electronic health care databases analyses AEDs prescribed to over 1 million pregnant women from the UK, France and Italy; 2007-16.
* AED prescribing during pregnancy was 3.0 (2.8-3.1) per 1,000 in Emilia Romagna, 5.9 (5.6-6.1) in Tuscany, 6.3 (5.7-6.9) in France and 7.8 (7.5-8.0) in the UK.
* Valproate was prescribed to 28.6% of AED exposed pregnant women in Tuscany, 21.6% in France, 16.7% in Emilia Romagna and 11.9% in the UK.
* Variations in AED prescribing including that of valproate during pregnancy indicate the potential for reductions in some regions.

Word Count: 6099

# Abstract

**Purpose**

To study patterns of Antiepileptic drugs (AED) prescribing, particularly valproate, during pregnancy over a 10 year-period in the UK, Italy and France.

**Methods**

Data on pregnancies conceived after 1st January 2007 with outcomes before 31st December 2016 were extracted from four European electronic healthcare databases (380,499 in the United Kingdom (UK), 66,681 in France and 649,918 in Italy [355,767 in Emilia Romagna and 294,151 in Tuscany]). Prevalence of AEDs with an ATC code starting N03A and clobazam (N05BA09) were stratified by country and calendar year.

**Results**

AED prescribing during pregnancy varied from 3.0 (2.8-3.1) per 1,000 pregnancies in Emilia Romagna to 7.8 (7.5-8.0) in the UK, 5.9 (5.6-6.1) in Tuscany and 6.3 (5.7-6.9) in France. Lamotrigine was commonly prescribed in all regions with a third of women exposed to an AED during pregnancy taking lamotrigine in the UK and France. Valproate was prescribed to 28.6% of AED exposed pregnant women in Tuscany, 21.6% in France, 16.7% in Emilia Romagna and 11.9% in the UK. Over the study period the prevalence of AED prescribing increased in the UK mainly due to increases in pregabalin and gabapentin; declined in France mainly related to decreases in clonazepam and remained constant in Italy. Valproate prescriptions declined to a prevalence <1 per 1,000 pregnancies in 2015-2016 in the UK, France and Emilia Romagna.

**Conclusions**

Variations in AED prescribing during pregnancy indicate the potential for further reductions, particularly of valproate. Increases in pregabalin/gabapentin prescribing, for which risks are not well-known, is a cause for concern.

# Introduction

Drugs classified as “Antiepileptics” in the Anatomical Therapeutic Chemical (ATC) classification may be indicated in several disorders depending on the country: epilepsy, bipolar disorder, anxiety, neuropathic pain and migraine prophylaxis. A recent European study, involving the United Kingdom (UK), France and Italy, showed that 1.2% to 2.9% of women of childbearing age received a prescription for a drug from the antiepileptic drugs (AED) ATC class in 20161.

It is now well demonstrated that exposure to some AEDs during pregnancy increases the risk of major congenital malformations in the offspring, such as neural tube defects and cleft palate, from two- to three-fold2–5. The risk varies by AED6: valproate is known to have the highest risk2 whereas lamotrigine may represent the safest AED during pregnancy5. Furthermore, since the early 2000s, several studies have suggested a risk of neurodevelopmental problems in children exposed *in-utero* to valproate7 including delayed walking and talking or difficulty with language3,8,9. *In-utero* valproate exposure can also affect intelligence quotient (IQ)10, can increase the risk of autistic spectrum disorder11,12 and possibly the risk of attention deficit hyperactivity disorder (ADHD)13, although these data are more limited.

In October 2014, following the warnings from the European Medicines and Healthcare products Regulatory Agency (MHRA) about the risks associated with the use of valproate in girls capable of becoming pregnant and women of childbearing potential, the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) issued recommendations for valproate prescribing14. The recommendations included that valproate and related substances (valproic acid, valproate and valpromide) should not be used in girls, women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated; valproate and related substances should be contraindicated in prophylaxis of migraine attacks in pregnancy and women of childbearing potential who are not using effective methods of contraception.

These guidelines were relayed by the EMA and by Health Authorities in European countries such as in the UK where a guide was published for healthcare professionals in January 201515 and in France where several letters have been sent to healthcare professionals since December 201416,17, and in Italy by the Italian National Medicines Agency (AIFA). Simultaneously, recommendations and blackbox warnings for valproate prescribing during pregnancy were disseminated by the Food and Drug Administration (FDA) in the United States18–20.

The present descriptive drug utilisation study, capturing data from three European countries (UK, Italy and France), aims to study patterns of AED prescribing, particularly valproate, during pregnancy over a 10 year-period. The objective consisted in providing prevalence of AED prescribing during pregnancy by country, by specific AEDs and by indications and also to describe evolution over time.

# Methods

## *Study design*

The study is a descriptive drug utilisation study, from 1 January, 2007 to 31 December, 2016.

## *Data source*

Anonymous data from linked electronic healthcare databases from four regions/countries contributed to the study: the UK (Clinical Practice Research Datalink (CPRD), capturing a sample of approximately 8% of the UK population), France (Echantillon Generaliste des Beneficiaires (EGB): French Health Insurance System and Hospital Medical Information Systems (PMSI), concerning a representative 1/97 sample of the French Population), Emilia Romagna in Italy (Certificate of Delivery Assistance (CeDAP) and Emilia-Romagna Prescription Database (ERPD)) and Tuscany in Italy (CeDAP, Hospital Discharges Registry and Tuscany Prescription Database (TPD)). An overview of the databases has been reported in previous articles1,21. Ethical and data access approvals were obtained for each database from the relevant governance infrastructures.

## *Pregnancy*

All pregnancies with a known pregnancy outcome were included. The start and end dates of each pregnancy in women aged between 10 and 50 years were identified within each of the databases during the study period using database specific algorithms. In the UK CPRD the algorithm incorporated all pregnancy related codes in the mother’s electronic medical record. In the Italian databases, the start of pregnancy was determined based on gestational age data and in the French database, the start of pregnancy was determined from information on gestational age or an algorithm incorporating other available pregnancy related data. In the UK, French and Tuscany databases, pregnancies that ended in a live birth, stillbirth, spontaneous abortion and induced termination (including those induced for non-medical reasons) were identifiable. In Emilia Romagna, pregnancy data were limited to those pregnancies ending in a live or stillbirth.

Multiple pregnancies were also included. Pregnancies were eligible for inclusion if the woman had been present in the study cohort for the 6 months before pregnancy and throughout the pregnancy.

## *Exposure to antiepileptic drugs (AEDs)*

AEDs with an ATC classification code starting with N03A and also clobazam (N05BA09) were used. These drugs can be licensed, depending on the countries, for epilepsy but also for bipolar disorder, anxiety, migraine prophylaxis and neuropathic pain.

AED exposure was based on the issue (UK) or the dispensing (France and Italy) of a prescription. Prescription duration and dose were not taken into account. Women were considered to be exposed to AEDs if they had received at least one prescription during the pregnancy. Considering the period of exposure during pregnancy, women were considered to be exposed during trimester 1 if they had received at least one prescription during the first 3 months of pregnancy, in trimester 2 if they had received a prescription during months 4-6 and in trimester 3 if they had received a prescription from month 6 to the end of pregnancy.

Valproate, including prescriptions for valproic acid and valpromide, was of particular interest.

## *Indications of AED prescriptions*

Indications for prescriptions were not available, or only partially available, in the four databases used for this study. Consequently, each country/region developed a specific algorithm to determine indications for AED prescriptions, using medical information available such as medical diagnoses, hospital discharge data, special reimbursement status or exemption codes, information on the type of prescriber, the specific name of the medicine and co-prescribing of other medicines. However, in Emilia Romagna and in Tuscany 31% and 49% of the indications could not be identified; consequently, only French and UK indication data were analysed.

## Statistical Methods

Prevalence of AED prescribing were computed overall and for specific AEDs, stratified by country/region and calendar year at pregnancy start. The number of pregnancies in 2016 was low as generally only pregnancies conceived before April had outcomes before the end of the year. Prevalence were calculated per 1,000 pregnancies (expressed with the symbol ‰), with 95% confidence intervals (CI95) calculated using the binomial distribution.

Data were analyzed using STATA 15 in the UK and SAS (SAS Institute, North Carolina, USA) in France and Italy.

# RESULTS

During the study period, more than one million pregnancies were captured in the databases: 66,681 pregnancies in France, 294,151 in Tuscany (Italy), 355,767 in Emilia Romagna (Italy) and 380,499 in the UK.

## *Prevalence of AED prescribing during pregnancy*

The prevalence of AED prescribing during pregnancy varied between countries/regions from 3.0 (2.8-3.1) per 1,000 pregnancies in Emilia Romagna to 7.8 (7.5-8.0) in the UK, with 5.9 (5.6-6.1) in Tuscany and 6.3 (5.7-6.9) in France.

As presented in the Table 1,lamotrigine was one of the 4 most commonly prescribed AEDs in all regions and the highest-prescribed AED in France and the UK. In France, 29.1% of women exposed to an AED during pregnancy and 33.2% in the UK were exposed to lamotrigine.

In Tuscany, valproate was the most frequently prescribed AED during pregnancy with 28.6% of pregnant women exposed to an AED being prescribed it, compared to 11.9% in the UK, 16.7% of women in Emilia Romagna, and 21.6% in France.

Clonazepam, carbamazepine and levetiracetam were also commonly prescribed in Italy, France and the UK during pregnancy. For more than 10% of pregnant women exposed to an AED, clonazepam was prescribed in Italy (14.9% in Emilia Romagna and 13.7 in Tuscany) and France (18.2%). The same applied to levetiracetam in France (10.7%), Emilia Romagna (10.6%) and the UK (12.9). Carbamazepine was prescribed for more than 15% of pregnant women exposed to an AED in Emilia Romagna (22.2%), UK (16.4%) and Tuscany (15.1%).

In France and the UK, pregabalin prescribing concerned respectively 12.6% and 13.4% of pregnant women exposed to an AED.

The prevalence of AED prescribing during pregnancy increased with age in all countries, particularly in women over 40 years of age in France and the UK. For example, in the UK, 15.2 per 1,000 pregnant women aged 45 years and older received an AED during their pregnancy. Gabapentin and pregabalin were largely responsible for this increase.

## *Prevalence of AED prescribing by trimesters of pregnancy (expressed per 1,000 pregnancies as ‰)*

In all regions, there was evidence of a decline in the prevalence of women exposed to an AED during pregnancy when compared to the 6-month period before the start of pregnancy and also a decline during early pregnancy (trimester 1 and trimester 2) (Figure 1). The prevalence of prescribing before pregnancy was highest in the UK (8.4‰) and France (8.0‰) and lowest in Emilia Romagna (3.0‰). The prevalence of prescribing in Tuscany was close to France during pregnancy, but higher than that observed in Emilia Romagna. The UK had the highest prevalence of AED prescribing in all 3 trimesters.

## *Prevalence of AED prescribing in relation to pregnancy by calendar year (expressed per 1,000 pregnancies as ‰)*

In the UK, the prevalence of AED prescribing increased more than 2-fold over the study period, with a greater increase occurring from 2012 mainly due to increases in pregabalin and gabapentin prescribing (Figure 2 and 3). After exclusion of pregabalin/gabapentin the prevalence of AED prescribing in the UK was relatively stable during the study period. In 2015, more than 2‰ of pregnant women received pregabalin or gabapentin prescriptions (2.3‰ and 2.7‰ respectively), compared with less than 1‰ in 2011 (0.8‰). This trend seems to be confirmed in 2016. To a lesser extent, an increase in lamotrigine prescribing was identifiable, with the prevalence increasing from 1.8‰ in 2007 to 3.4‰ in 2015. In contrast, a decline in valproate prescribing was observed, from 1.4‰ in 2007 to 0.6‰ in 2015.

In France, there was a general decline in the prescribing of any AED during the study period with a prevalence of 7.4‰ in 2007 and 5.4‰ in 2015. The greatest reduction occurred between 2008 and 2012 and was likely to be related to the large reductions in clonazepam prescribing. After exclusion of clonazepam, the prevalence of AED prescribing was relatively stable during the study period. For valproate, the prevalence of prescribing during pregnancy declined between 2009 and 2011 after which it has remained constant with a prevalence of 0.7‰ in 2015 and 2016. By contrast, prevalence of lamotrigine prescribing increased during the same period from 1.5‰ in 2007 to 2.6‰ in 2015.

In Italy, in both Emilia Romagna and Tuscany, Figure 2 shows AED prescribing was stable between 2007 and 2015. However, a small decline from 0.6‰ in 2007 to 0.3‰ in 2015 in valproate prescribing was identified in Emilia Romagna while in Tuscany AED prescribing decreased from 2.0‰ in 2007 to 1.4‰ in 2015.

## *Indications*

In the French and UK databases, 4.2‰ and 4.8‰ of pregnant women respectively received an AED for the treatment of epilepsy (278 out of a total of 66,681 pregnancies in France and 1,826 out of 380,499 in the UK) (Table 2). They represent 65.9% and 61.8% respectively of the women exposed to AEDs during pregnancy, while 16.4% received AEDs for bipolar disorder in France compared with 5.4% in the UK and 11.6% for pain in France compared with 15.4% in the UK (including 8.6% for neuropathic pain). Other indications were less frequent, with for example only 2.8% and 2.4% of women who received an AED due to an anxiety disorder. About 9% and 12.8% of indications were not identifiable in France and the UK respectively.

Among women exposed to valproate during pregnancy in France, only prescriptions for bipolar disorder and epilepsy could be identified with 73.6% of them treated for epilepsy and 26.4% for bipolar disorder. In the UK, 77.1% of women exposed to valproate during pregnancy were treated for epilepsy, 15.9% for bipolar disorder, 4.8% with unknown indications and the remaining 2.2% for migraines and other psychiatric disorders.

# DISCUSSION

## *Exposure to AEDs during pregnancy: differences between European countries*

More than one million pregnancies were identified in the three European countries including over 6,000 pregnant women who received an AED (around 6 per 1,000). The prevalence of AED prescribing during pregnancy varies between regions and ranges from 3 per 1,000 in Emilia Romagna to almost 8 per 1,000 in the UK. In the UK, the prevalence was slightly higher and in Emilia Romagna slightly lower than that reported by a previous EUROmediCAT study, which used the same databases (excluding France) but covered an earlier time period from 2004 to 201022. The UK prevalence was also higher than that reported in another UK-based study between 1994 and 200923. In France, the prevalence of AED and valproate prescribing were in line with figures reported by recent studies using the national health insurance database linked to hospitalization data24.

## *Fewer AED prescriptions in Europe than in the United States during pregnancy*

The prevalence of AED prescribing during pregnancy in all four regions was around 3 times less than that reported in a US-based study25where an increase in the prevalence of AED use was observed between 2001 and 2007, partly explained by an increase in the prescribing of lamotrigine and gabapentin. The US study used data from the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP), a collaborative program between the US Food & Drug Administration (FDA) and researchers from different institutions concerning around 12 million individuals enrolled within nine states, covering geographically and demographically diverse populations.

## *Heterogeneous evolution between European countries*

There was an increase over time in the prevalence of AED use during pregnancy in the UK due to a sharp increase in prescribing of gabapentin and pregabalin. This situation was also observed, to a lesser extent, for pregabalin in France, showing a new trend of AED prescribing. Concerning gabapentin, data in human pregnancy are insufficient to conclude whether or not there is a potential risk to the fetus26. Concerning pregabalin, studies in rats have shown adverse effects on embryo-fetal development and a signal for increased risk of major birth defects was reported27 but not confirmed thereafter28. Moreover, pregabalin and gabapentin present a potential for abuse and dependence29 as mentioned in advice for prescribers disseminated in the UK, from late 201430. Therefore, further investigations into their use and safety in pregnancy should be performed.

In Italy, the prevalence of AED use during pregnancy remained stable, while in France, the decline in AED prescriptions over time was mainly due to the decline in clonazepam prescriptions linked to changes in the rules on prescribing in 2011-2012 to prevent abuse and misuse31. These trends were also observed in the recent study concerning women of childbearing potential using the same databases1.

## *Prescription of AED mainly for the treatment of epilepsy during pregnancy*

Indications were not available in the electronic healthcare databases and algorithms to identify indications could only be developed successfully for France and the UK. In France 4 per 1,000 French pregnant women were treated by AEDs for epilepsy. This is consistent with a previous study, carried out in another European country, which showed that around 3 in 1,000 pregnant women suffer from epilepsy32. The figures were similar for pregnant women in the UK.

Over 60% of French and UK pregnant women exposed to AEDs were treated for the indication “epilepsy”, compared with 31% of the general population of women of childbearing potential 1. This can be explained by the fact that, in Europe, it is recommended that the use of these medications during pregnancy must be limited to the cases where no other treatment is effective, a situation which occurs especially for women with epilepsy.

In contrast, in the US, psychiatric disorders were the most prevalent diagnoses in pregnant women exposed to AED, followed by epilepsy and pain25.

## *Drug choice differs according to countries*

In all regions, valproate prescriptions were issued to at least 10% of women exposed to an AED during pregnancy and almost 30% in Tuscany, where valproate was the most frequently prescribed AED throughout the entire study period. From 2007 to 2016 all regions, with the exception of Tuscany, observed a slight decreasing prevalence of valproate prescribing during pregnancy as reported in previous general population studies in Ireland and the UK33,34. However, since 2013 for Italy and 2014 for France and the UK several warnings around valproate have been published each year by National Medicines Agencies [on the AIFA (Italian Medicines Agency) website in Italy, on the ANSM (French Medicines Agency) website in France and on the MHRA (Medicines and Healthcare products Regulatory Agency) website for the UK] and risks associated with valproate exposure during pregnancy have been described in the scientific literature since the 1980s.

A significant number of newborns are still exposed in utero to valproate despite the recommendations. It may be that the “minimal essential level” of valproate exposure in pregnant women has been reached (less than 1 per 1,000 pregnant women in 2015-2016 in the UK, France and Emilia Romagna) and that all exposures are to women where no other treatment is effective. However, it remains important to inform health professionals to try to further reduce exposure to valproate to women of childbearing age.

Lamotrigine is the most frequently-prescribed AED in France and the UK, with respectively one-quarter and one-third of AED exposed women exposed to this AED which is in the top 4 of the most prescribed AEDs during pregnancy in all regions. Moreover, this drug appears to be increasingly used over time as observed previously in Denmark, Norway and Wales22 and Australia35. This situation is rather reassuring because several reviews have concluded that lamotrigine may be associated with a lower risk of teratogenicity36,37. In 2009, an increased risk of cleft palate and lip was reported after an exposure during the first trimester of pregnancy38. However, this risk was not confirmed by other studies39.

During the first years of the study period, **c**arbamazepine was the most frequently prescribed-AED in Emilia Romagna, with more than 20% of pregnant women exposed to AEDs receiving carbamazepine. Carbamazepine use in pregnancy is associated with an increased risk of malformations (RR=2.2)40, including neural tube defects, cardiovascular and urinary tract defects, and cleft palate41,42.

## *Fewer AED prescriptions in pregnant women than in the general population of women*

 The 2 fold lower use of AEDs during the 6 months preceding the start of pregnancy may indicate that these pregnancies are planned. However, some women who have an AED prescription in early pregnancy (the most risky period for congenital anomalies) have no more prescriptions during the 2nd and the 3rd trimesters, suggesting that the AED treatment can be stopped or replaced. This emphasises the need of systematic counselling of epileptic women of childbearing age.

## *Study with some weaknesses but representative of European population*

Healthcare administrative databases allow comparison studies between countries to be conducted. However, some weaknesses are linked to the use of these databases1, in particular the absence of data on compliance with treatment and on prescriptions during hospital stays. Prescription duration and dose were not available and AED exposure was based solely on the issue or the dispensing of at least one prescription during individually specified 3 month periods relating to the pregnancies. In France, AED medications are dispensed each month by the pharmacist, irrespective of the duration of the prescription. The patient returns to the pharmacy each month to get that month’s AED medication and therefore exposure during the three months will be reported. In Emilia Romagna (Italy), pharmacists can dispense a two-month supply of any medication and in the UK medications can also be dispensed for different durations, but are extremely unlikely to be for more than 3 months at a time. Therefore, exposure during any specified three month period is also likely to be captured in these databases.

The underlying disease for which the prescription was issued was often not available in the databases, raising the need to develop and validate algorithms to determine indications for prescribing. For drugs with several indications, like AEDs, where the benefit/risk balance for adverse pregnancy outcomes could be different according to the maternal disease, lack of indication can represent a limitation for the interpretation of pregnancy medication safety studies. Moreover, prevalence of AED prescribing in Emilia Romagna must be considered with caution because pregnancy data were limited to those pregnancies ending in livebirth or stillbirth. In other countries, spontaneous abortions, induced terminations and unknown losses represent between 20 and 30% of pregnancies included in the study. Likewise, prevalence rates in 2016 must be treated with caution since they concern only a few pregnancies (only those pregnancies which start in 2016 and finish in 2016). Although they represent a rich source of information, administrative healthcare databases, such as those used here, were not designed to perform research studies. Algorithms had to be used to calculate start and end dates of the pregnancy; consequently, estimations of exposure periods may not be always accurate.

The UK and French databases used in this study are broadly representative samples of the general population of these countries (around 8% of the UK population and around 1% of the French population). However, in Italy, dispensed prescriptions of 2 different regions only were captured and women included may not be representative of the general Italian population.

Nevertheless, the major strength of this study is that it concerned more than one million pregnancies from 4 European regions allowing patterns of AED prescription during pregnancy to be compared in countries with different guidance on prescribing, recommendations15,17 and lifestyles.

## Future Recommendations

During the 10 year period physicians were increasingly drawing on new drugs like pregabalin or gabapentin. However, risks associated with the use of these drugs during pregnancy are not well-known due to the lack of relevant studies. Further evaluation on their effects during pregnancy is needed. Until then, healthcare practitioners should limit their prescriptions of pregabalin and gabapentin during pregnancy.

Observed differences in the prevalence of AED exposure, particularly valproate, during pregnancy indicate that information on the risks associated with these exposures should continue to be further disseminated to reduce the exposure levels. Safety information should also highlight that valproate is contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control and a pregnancy prevention plan is in place.

##  Conclusion

Although the prevalence of AED prescribing during pregnancy varied between European countries, during the 10 year period, prescriptions for valproate during pregnancy decreased. However, at least 10% of pregnant women receiving an AED prescription in the study were prescribed valproate, hence there is further potential for reduction. At the same time, AED prescriptions for pregabalin and gabapentin, for which risks for the embryo or the fetus are not well-known, increased. Information on risks associated with exposure to valproate during pregnancy should continue to be widely circulated to health care providers, and studies on potential alternative medications should be promptly conducted.

**ACKNOWLEDGEMENTS**

The authors are very grateful for the input in the study design and analysis from the other members of the EUROmediSAFE consortium: Dr Vera Nelen, Dr Els Van de Mieroop, Dr Babak Khoshnood, Dr Pascale Tubert-Bitter, Dr Nathalie Lelong, Dr Anke Rissmann, Dr Jorieke van Kammen-Bergman, Dr Jen Bos, Prof Sue Jordan, Prof Helen Dolk and Prof Marlene Sinclair and from Dr Anita McGrogan.

**CONFLICTS OF INTEREST**

This document expresses the opinion of the authors of the paper, and may not be understood or quoted as being made on behalf or of reflecting the position of the European Medicines Agency or one of its committees or working parties.

**FUNDING**

This work was supported by the European Medicines Agency (EMA) grant number EMA/2015/25/PH.

**AUTHOR CONTRIBUTION**

Rachel Charlton and Julia Snowball performed the analysis in the UK, Caroline Hurault-Delarue in France, Rosa Gini in Tuscany (Italy) and Aurora Puccini in Emilia Romagna (Italy). Rachel Charlton and Joan K Morris coordinated the project, wrote the protocol, collected and interpreted the results; they wrote the study report. Caroline Hurault-Delarue and Joan K Morris wrote the manuscript with support from Christine Damase-Michel. All authors discussed the protocol and the results and commented on the final manuscript.

**AVAILABILITY OF DATA AND MATERIAL**

The authors are willing to consider reasonable requests for access to the aggregate data used in the analysis in this paper.

# REFERENCES

1. Charlton R, Damase-Michel D-M, Hurault-Delarue C, et al. Prescriptions of antiepileptic medications in women in three European countries between 2007 and 2016 : effect of a warning concerning valproate. 2018; .

2. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006; 77(2):193‑8.

3. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008; 81(1):1‑13.

4. Thomas SV, Jose M, Divakaran S, et al. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India. Epilepsia. 2017; 58(2):274‑81.

5. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016; 11:CD010224.

6. Bromley RL, Weston J, Marson AG. Maternal Use of Antiepileptic Agents During Pregnancy and Major Congenital Malformations in Children. JAMA. 2017; 318(17):1700‑1.

7. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014; (10):CD010236.

8. Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav EB. 2009; 15(3):339‑43.

9. Thomas SV, Sukumaran S, Lukose N, et al. Intellectual and language functions in children of mothers with epilepsy. Epilepsia. 2007; 48(12):2234‑40.

10. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013; 12(3):244‑52.

11. Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16):1696‑703.

12. Rasalam AD, Hailey H, Williams JHG, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005; 47(8):551‑5.

13. Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years. Epilepsy Behav EB. 2013; 29(2):308‑15.

14. PRAC recommends strengthening the restrictions on the use of valproate in women and girls - WC500175208.pdf [Internet]. [cité 2018]. Disponible sur: http://www.ema.europa.eu/docs/en\_GB/document\_library/Press\_release/2014/10/WC500175208.pdf

15. Medicines related to valproate: risk of abnormal pregnancy outcomes [Internet]. GOV.UK. [cité 2018]. Disponible sur: https://www.gov.uk/drug-safety-update/medicines-related-to-valproate-risk-of-abnormal-pregnancy-outcomes

16. Valproate et dérivés (Dépakine®, Dépakote®, Dépamide®, Micropakine® et génériques) : risque d’issues anormales de grossesse - Lettre aux professionnels de santé - ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 2018]. Disponible sur: http://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Valproate-et-derives-Depakine-R-Depakote-R-Depamide-R-Micropakine-R-et-generiques-risque-d-issues-anormales-de-grossesse-Lettre-aux-professionnels-de-sante

17. Valproate et dérivés : contre-indication pendant la grossesse (sauf situations exceptionnelles) et programme de prévention des grossesses - Lettre aux professionnels de santé - ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 2018]. Disponible sur: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Valproate-et-derives-contre-indication-pendant-la-grossesse-sauf-situations-exceptionnelles-et-programme-de-prevention-des-grossesses-Lettre-aux-professionnels-de-sante

18. Prescribing information on valproic acid - Black box (FDA) [Internet]. [cité 2019]. Disponible sur: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2019/018081s069,018082s052lbl.pdf

19. FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children. FDA [Internet]; Available on: http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-valproate-anti-seizure-products-contraindicated-migraine-prevention

20. FDA Drug Safety Communication: Valproate Information. FDA [Internet]; Available on: http://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/valproate-information

21. Charlton RA, Neville AJ, Jordan S, et al. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf. 2014; 23(6):586‑94.

22. Charlton R, Garne E, Wang H, et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015; 24(11):1144‑54.

23. Man S-L, Petersen I, Thompson M, et al. Antiepileptic drugs during pregnancy in primary care: a UK population based study. PloS One. 2012; 7(12):e52339.

24. Exposition in utero à l’acide valproïque et aux autres traitements de l’épilepsie et des troubles bipolaires et risque de malformations congénitales majeures (MCM) en France - fb3faa8c4a5c5c5dedfc1423213c219d.pdf [Internet]. [cité 2018]. Disponible sur: http://ansm.sante.fr/var/ansm\_site/storage/original/application/fb3faa8c4a5c5c5dedfc1423213c219d.pdf

25. Bobo WV, Davis RL, Toh SD, et al. Trends in the use of antiepileptic drugs (AEDs) among pregnant women in the U.S., 2001-2007: a Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) study. Paediatr Perinat Epidemiol. 2012; 26(6):578‑88.

26. de Jong J, Garne E, de Jong-van den Berg LTW, et al. The Risk of Specific Congenital Anomalies in Relation to Newer Antiepileptic Drugs: A Literature Review. Drugs - Real World Outcomes. 2016; 3(2):131‑43.

27. Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016; 86(24):2251‑7.

28. Patorno E, Bateman BT, Huybrechts KF, et al. Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology. 2017; 88(21):2020‑5.

29. Caster O, Edwards IR, Norén GN, et al. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol. 2011; 67(3):319‑20.

30. Pregabalin and gabapentin: advice for prescribers on the risk of misuse [Internet]. GOV.UK. [cité 2018]. Disponible sur: https://www.gov.uk/government/publications/pregabalin-and-gabapentin-advice-for-prescribers-on-the-risk-of-misuse

31. Rivotril (clonazépam) : Modification des conditions de prescription et de délivrance - Lettre aux professionnels de santé - Actualisé le 04/01/2012 - ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cité 2018]. Disponible sur: http://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Rivotril-clonazepam-Modification-des-conditions-de-prescription-et-de-delivrance-Lettre-aux-professionnels-de-sante-Actualise-le-04-01-2012

32. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of Women with Epilepsy: A Population‐Based Study in Iceland. Epilepsia. 1998; 39(8):887‑92.

33. Murphy S, Bennett K, Doherty CP. Prescribing trends for sodium valproate in Ireland. Seizure. 2016; 36:44‑8.

34. Ackers R, Besag FMC, Wade A, et al. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch Dis Child. 2009; 94(6):443‑7.

35. Vajda FJE, Hollingworth S, Graham J, et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand. 2010; 121(2):89‑93.

36. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med. 1996; 334(24):1583‑90.

37. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and fetal outcome. Epilepsia. 1996; 37 Suppl 6:S34-44.

38. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008; 70(22 Pt 2):2152‑8.

39. Pariente G, Leibson T, Shulman T, et al. Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. CNS Drugs. 2017; 31(6):439‑50.

40. Diav-Citrin O, Shechtman S, Arnon J, et al. Is carbamazepine teratogenic? A prospective controlled study of 210 pregnancies. Neurology. 2001; 57(2):321‑4.

41. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med. 1991; 324(10):674‑7.

42. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989; 320(25):1661‑6.

**Table 1 –** Proportion of each specific AED prescription per 100 AED exposed women during pregnancy in each region

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | **Emilia Romagna** | **Tuscany** | **France** | **United Kingdom** |
|  | **N** | **%**  | **N** | **%**  | **N** | **%**  | **N** | **%**  |
|  | **Any AED** | **1,057a** | **100.0%** | **1,722b** | **100.0%** | **422c** | **100.0%** | **2,956d** | **100.0%** |
| Lamotrigine  | N03AX09 | 197 | 18.6% | 221 | 12.8% | 123 | 29.1% | 980 | 33.2% |
| *Any valproate* |  | *177* | *16.7%* | *492* | *28.6%* | *91* | *21.6%* | *353* | *11.9%* |
|  Valproic acid | N03AG01 | 172 | 16.3% | 490 | 28.5% | 74 | 17.5% | 353 | 11.9% |
|  Valpromide  | N03AG02 | 5 | 0.5% | 2 | 0.1% | 18 | 4.3% | 0 | -- |
| Carbamazepine  | N03AF01 | 235 | 22.2% | 260 | 15.1% | 31 | 7.3% | 485 | 16.4% |
| Pregabalin  | N03AX16 | 61 | 5.8% | 149 | 8.7% | 53 | 12.6% | 395 | 13.4% |
| Levetiracetam  | N03AX14 | 112 | 10.6% | 115 | 6.7% | 45 | 10.7% | 382 | 12.9% |
| Gabapentin  | N03AX12 | 36 | 3.4% | 102 | 5.9% | 16 | 3.8% | 429 | 14.5% |
| Clonazepam | N03AE01 | 158 | 14.9% | 236 | 13.7% | 77 | 18.2% | 72 | 2.4% |
| Topiramate  | N03AX11 | 72 | 6.8% | 113 | 6.6% | 20 | 4.7% | 183 | 6.2% |
| Phenobarbital | N03AA02 | 80 | 7.6% | 174 | 10.1% | 6 | 1.4% | 6 | 0.2% |
| Oxcarbazepine  | N03AF02 | 44 | 4.2% | 82 | 4.8% | 10 | 2.4% | 15 | 0.5% |
| Clobazam | N05BA09 | 5 | 0.5% | 0 | -- | 44 | 10.4% | 91 | 3.1% |

On a total of *a*: 355,767 pregnancies (3.0‰); *b*: 294,151 pregnancies (5.9‰); *c:* 66,681 pregnancies (6.3%); *d:* 380,499 pregnancies (7.8‰)**Table 2 – Indications of AED prescriptions during pregnancy in France and United Kingdom**

|  |  |  |
| --- | --- | --- |
|  | **France** | **United Kingdom** |
|   | **N** | **%**  | **N** | **%**  |
| **Any AED** | **422** | **100.0%** | 2,956 | 100.0% |
| Epilepsy | 278 | 65.9% | 1,826 | 61.8% |
| Bipolar disorder | 69 | 16.4% | 161 | 5.4% |
| Anxiety | 12 | 2.8% | 72 | 2.4% |
| Pain | 49 | 11.6% | 457 | 15.4% |
| Migraine | 3 | 0.7% | 66 | 2.2% |
| Gen psych |   |   | 57 | 1.9% |
| Unknown | 38 | 9.0% | 377 | 12.8% |

**FIGURE LEGENDS**

**Figure 1** - Prevalence of AED prescribing during each of the pregnancy trimesters and the 6 months before the start of pregnancy by region

**Figure 2** - Prevalence of AED prescribing during pregnancy by year from 2007 to 2016

**Figure 3** - Prevalence of AED prescribing during pregnancy by country and by year from 2007 to 2016